SlideShare uma empresa Scribd logo
1 de 20
Co-Valtin 5/80, 5/160 
(Amlodipine BP 5 mg & Valsartan USP 80/160 mg) 
Presented by 
Mohammed Moshiur Rahaman 
Senior Brand Executive 
Brand Management Department 
Strategic Brand Management Division 
The ACME Laboratories Ltd.
Co-Valtin 
(Amlodipine BP & Valsartan USP) 
Combination of 
Amlodipine & Valsartan
Price & Supply 
Price: 5/80 mg (09 taka) 
5/160 mg (16 taka) 
Supply: 3x10 tablets 
Product Group : B
 Hypertrophy is the increase in the volume of an 
organ or tissue due to the enlargement of its 
component cells. 
 Fibrosis is the formation of excess fibrous 
connective tissue in an organ or tissue in a reparative 
or reactive process. This can be a reactive, benign, 
or pathological state.
Valsartan & Amlodipine (2Q, 2014) 
Total market size is 15.5 crore with 
46% positive growth 
Generic Company Market 
(Crore) 
Growth 
Amlosartan Incepta 6.43 41 
Amlovas-VS Popular 3.40 22 
Exforge Novartis 2.42 223 
Camoval Square 2.01 50
Indication 
For the treatment of hypertension 
Dosage & Administration 
 1 tablet per day OR may be increased 
after 1-2 weeks to a maximum of 10/320 
mg 
 No dosage adjustment for mild to 
moderate hepatic & renal impairment.
Target doctors 
Cardiologist 
Endocrinologist 
Neurologist 
Medicine specialist 
Nephrologist
Atrial fibrillation is the most common 
abnormal heart rhythm. It may cause no 
symptoms, but is often associated with 
palpitations, chest pain, or congestive 
heart failure.
Thank you

Mais conteúdo relacionado

Destaque

Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010
Dario Adames
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
Muhammad Aun
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
BALASUBRAMANIAM IYER
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
Satyajit Hui
 

Destaque (20)

Valzaar (Valsartan Tablets)
Valzaar (Valsartan Tablets)Valzaar (Valsartan Tablets)
Valzaar (Valsartan Tablets)
 
Novartis master minds 2009 final
Novartis master minds 2009 finalNovartis master minds 2009 final
Novartis master minds 2009 final
 
Are all sartans equal
Are all sartans equalAre all sartans equal
Are all sartans equal
 
Medical device-Gastric banding- presented at Humber-By Shally bhardwaj
Medical device-Gastric banding- presented at Humber-By Shally bhardwajMedical device-Gastric banding- presented at Humber-By Shally bhardwaj
Medical device-Gastric banding- presented at Humber-By Shally bhardwaj
 
Hypertension the silent killer
Hypertension the silent killer Hypertension the silent killer
Hypertension the silent killer
 
Ht Nlecture2009
Ht Nlecture2009Ht Nlecture2009
Ht Nlecture2009
 
Olmecip (Olmesartan Medoxomil Tablets)
Olmecip (Olmesartan Medoxomil Tablets)Olmecip (Olmesartan Medoxomil Tablets)
Olmecip (Olmesartan Medoxomil Tablets)
 
Irbesartan
IrbesartanIrbesartan
Irbesartan
 
Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010
 
Literature Survey & Market Survey on Amlodipine and its Recent Trends
Literature Survey & Market Survey on Amlodipine and its Recent TrendsLiterature Survey & Market Survey on Amlodipine and its Recent Trends
Literature Survey & Market Survey on Amlodipine and its Recent Trends
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
 
Sacubitril valsartan EK
Sacubitril valsartan EKSacubitril valsartan EK
Sacubitril valsartan EK
 
Januvia by shally bhardwaj
Januvia by shally bhardwajJanuvia by shally bhardwaj
Januvia by shally bhardwaj
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 
Aliskiren And Valsartan
Aliskiren And ValsartanAliskiren And Valsartan
Aliskiren And Valsartan
 
De la evidencia científica a las recomendaciones clínicas
De la evidencia científica a las recomendaciones clínicasDe la evidencia científica a las recomendaciones clínicas
De la evidencia científica a las recomendaciones clínicas
 
ueda2011 hf to mi -d.samer sayed
ueda2011 hf to mi -d.samer sayedueda2011 hf to mi -d.samer sayed
ueda2011 hf to mi -d.samer sayed
 
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline UpdatesJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
 
Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009
 

Semelhante a Co valtin

Lupin Corporate Small
Lupin Corporate SmallLupin Corporate Small
Lupin Corporate Small
venkychetty
 

Semelhante a Co valtin (17)

Atorvastatin Brand Available In Butwal
Atorvastatin Brand Available In ButwalAtorvastatin Brand Available In Butwal
Atorvastatin Brand Available In Butwal
 
Intas Biopharma Brochure
Intas Biopharma BrochureIntas Biopharma Brochure
Intas Biopharma Brochure
 
Pharmaceutical prospectives of anti estrogen, m-tor, CDK 4/6 in Breast Cancer
Pharmaceutical prospectives of anti estrogen, m-tor, CDK 4/6 in Breast CancerPharmaceutical prospectives of anti estrogen, m-tor, CDK 4/6 in Breast Cancer
Pharmaceutical prospectives of anti estrogen, m-tor, CDK 4/6 in Breast Cancer
 
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
 
Licencing & drug recall of 2014 & 2015
Licencing & drug recall of 2014  & 2015 Licencing & drug recall of 2014  & 2015
Licencing & drug recall of 2014 & 2015
 
Buy erlonat 150 mg
Buy erlonat 150 mgBuy erlonat 150 mg
Buy erlonat 150 mg
 
Atorvastatin- Cholesterol lowering drug
Atorvastatin- Cholesterol lowering drugAtorvastatin- Cholesterol lowering drug
Atorvastatin- Cholesterol lowering drug
 
Altamofen Tablets (Generic Tamoxifen Citrate Tablets)
Altamofen Tablets (Generic Tamoxifen Citrate Tablets)Altamofen Tablets (Generic Tamoxifen Citrate Tablets)
Altamofen Tablets (Generic Tamoxifen Citrate Tablets)
 
Warfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdiWarfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdi
 
Labor welfare measures of Elegant Drugs
Labor welfare measures of Elegant Drugs Labor welfare measures of Elegant Drugs
Labor welfare measures of Elegant Drugs
 
Lupin Corporate Small
Lupin Corporate SmallLupin Corporate Small
Lupin Corporate Small
 
OPES Company breif-2016
OPES Company breif-2016OPES Company breif-2016
OPES Company breif-2016
 
Polyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activityPolyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activity
 
Polyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activityPolyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activity
 
Pharmaceutical Industrial training ppt.pptx
Pharmaceutical Industrial training ppt.pptxPharmaceutical Industrial training ppt.pptx
Pharmaceutical Industrial training ppt.pptx
 
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
 
Uphar Specialty Pharma, Ahmedabad, Medicines
Uphar Specialty Pharma, Ahmedabad, MedicinesUphar Specialty Pharma, Ahmedabad, Medicines
Uphar Specialty Pharma, Ahmedabad, Medicines
 

Co valtin

  • 1. Co-Valtin 5/80, 5/160 (Amlodipine BP 5 mg & Valsartan USP 80/160 mg) Presented by Mohammed Moshiur Rahaman Senior Brand Executive Brand Management Department Strategic Brand Management Division The ACME Laboratories Ltd.
  • 2. Co-Valtin (Amlodipine BP & Valsartan USP) Combination of Amlodipine & Valsartan
  • 3. Price & Supply Price: 5/80 mg (09 taka) 5/160 mg (16 taka) Supply: 3x10 tablets Product Group : B
  • 4.
  • 5.
  • 6.  Hypertrophy is the increase in the volume of an organ or tissue due to the enlargement of its component cells.  Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state.
  • 7.
  • 8. Valsartan & Amlodipine (2Q, 2014) Total market size is 15.5 crore with 46% positive growth Generic Company Market (Crore) Growth Amlosartan Incepta 6.43 41 Amlovas-VS Popular 3.40 22 Exforge Novartis 2.42 223 Camoval Square 2.01 50
  • 9. Indication For the treatment of hypertension Dosage & Administration  1 tablet per day OR may be increased after 1-2 weeks to a maximum of 10/320 mg  No dosage adjustment for mild to moderate hepatic & renal impairment.
  • 10. Target doctors Cardiologist Endocrinologist Neurologist Medicine specialist Nephrologist
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17. Atrial fibrillation is the most common abnormal heart rhythm. It may cause no symptoms, but is often associated with palpitations, chest pain, or congestive heart failure.
  • 18.
  • 19.